ʻAʻole hiki i nā poʻe e loaʻa i ka diabetes mellitus type 2 ke hoʻomau mau i ka pae o ka glucose i kahi pae maʻamau ma muli o hoʻokahi ʻano hana pilikino a me nā meaʻai kūikawā e hoʻoleʻaleʻa mau i nā haʻalulu a me nā momona.
Hōʻike pinepine kēia ʻano me kahi ala lōʻihi o ka maʻi, ʻo kēlā me kēia makahiki ka hana pono o nā pancreas. A laila hele mai nā papa Galvus i ke hoʻopakele, kahi e hoʻemi ana a hoʻohemo i ke kō i loko o nā mea maʻamau.
Ua makemake nui nā maʻi maʻi maʻi āpau i ka hopena o ka lāʻau lapaʻau e pili ana i ka vildagliptin. No laila, e hōʻike aku kēia ʻatikala i ka hana o ka hana a me nā ʻano o kāna hoʻohana ʻana, i hiki ai i nā mea āpau ke hoʻopaʻa i no lākou iho i ke ʻano o ka lāʻau lapaʻau hypoglycemic.
Ka hana lāʻau lapaʻau
Vildagliptin (ʻ versionlelo Helene - Vildagliptinum) pili i ka papa o nā mea i hoʻowalewale i nā mokupuni o Langerhans ma nā pancreas a hoʻokaʻawale i ka hana o dipeptidyl peptidase-4. ʻO ka hopena o kēia enima ka meaʻino no ka peptide type 1 glucagon-like (GLP-1) a me ka glucose-dependotine insulin -ropyp -ide (HIP).
I ka hopena, ua hoʻomāka ʻia ka hana o dipeptidyl peptidase-4 e ka mea i hoʻonui ʻia, a hoʻonui ʻia ka hana o GLP-1 a me HIP. Ke hoʻonui ka nui o ko lākou koko, e hoʻomaikaʻi ka vildagliptin i ka hoʻololi ʻana o nā hua beta i ka glucose, e hoʻonui ai i ka hana o ka insulin. ʻO ka piʻiʻana o ka hoʻonui i ka hana o nā pū beta e pili pololei i ka pae o ko lākou hōʻino. No laila, i nā poʻe me nā waiwai maʻamau o ka hilo i ka wā e hoʻohana ai i nā lāʻau lapaʻau e pili ana me vildagliptin, ʻaʻole ia e pili i ka hana ʻana o ke kōpaʻa haʻahaʻa gula a, ʻoiaʻiʻo hoʻi, ka glucose.
Eia kekahi, i ka wā e hoʻonui ai ka lāʻau i nā mea e pili ana i ka GLP-1, i ka manawa like, e hoʻonui ka naʻau o ka glucose ma nā pūpū alpha. ʻO kēlā kaʻina hana e hoʻokomo i ka hoʻonui ʻana i ka hoʻoponopono o ka glucose i hilinaʻi ʻia o ka hana ʻana o nā cell alpha hormone, i kapa ʻia ʻo glucagon. ʻO ka hoʻohaʻahaʻa ʻana i kāna mau kumuhana i ka wā e hoʻohana ana i nā kīʻaha e kōkua i ka hoʻopau ʻana i ke kōpū o ka cell i ka insulin hormone.
Ke piʻi ka nui o ka insulin a me ka glucagon, i hoʻoholo ʻia e ka hoʻonui nui ʻana o ka HIP a me GLP-1, i ke kūlana hyperglycemic maʻi, hoʻomaka ka huaʻai i loko o ka ate ma ka liʻiliʻi o ka ʻai, ma ka wā o ka ʻai ʻana o ka meaʻai a ma hope o ia mea, e hoʻokau ana i ka hoʻemi o ka glucose i loko o ke kaila koko o ka maʻi maʻi.
Pono e hoʻomanaʻo, ma ka hoʻohana ʻana iā Vildagliptin, e kahe ana ka nui o ka lipum ma hope o ka ʻai ʻana. ʻO ka hoʻonui pinepine ʻia o nā ʻike o ka GLP-1 i kekahi mau manawa ke hōʻemi nei i ka hoʻokuʻu ʻana o ka ʻōpū, ʻoiai kahi hopena like ʻole i ʻike ʻia i ka wā o ka hoʻomaʻamaʻa ʻana.
Ua hōʻike ʻia kahi noi e pili ana i kahi 6,000 mau mea maʻi ma luna o 52 mau pule i ka hoʻohana ʻana o vildagliptin hiki i ka hoʻohaʻahaʻa i nā pae glucose i loko o kahi ʻōpū a me ka hemoglobin glycated (HbA1c) i ka wā i hoʻohana ʻia ka lāʻau lapaʻau.
- ke kumu o ka lapaʻau lāʻau;
- i ka hui me metformin;
- i ka hui me sulfonylureas;
- i ka hui me thiazolidinedione;
ʻO ka pae o ka glucose e hoʻēmi ana me ka hoʻohana pū ʻana o vildagliptin me ka insulin.
Nā ʻōkuhi no ka hoʻohana ʻana i nā papa
Ma ka mākeke lāʻau lapaʻau, hiki iā ʻoe ke ʻike i ʻelua mau lāʻau me ka vildagliptin.
ʻO ka ʻokoʻa i ka ʻenehana neʻe: i ka hana mua, ʻo ia wale nō ka vildagliptin, a i ka lua - vildagliptin, metformin.
ʻO ka mea hana o nā lāʻau lapaʻau ka hui Swiss Novartis.
Loaʻa ka lāʻau lapaʻau i loko o nā palapalaʻano hana:
- Vildagliptin me ʻole o nā ʻokoʻa hou (i nā papa 28 i mau ʻāpana i kahi pānaʻi o 50 mg);
- ʻO Vildagliptin i hui pū me Metformin (30 mau papa i kahi pānaʻi o 50/500, 50/850, 50/1000 mg).
ʻO ka mea mua, ʻo ke kanaka maʻi me ka maʻi diabetes-is-insulin-pono e kūkākūkā me ka mea lapaʻau lapaʻau nāna e kākau i kahi papa inoa ʻole me ka nele ʻole. Ma waho o ia, ʻaʻole hiki iā ʻoe ke loaʻa ka hopena. A laila e heluhelu pono ka mea maʻi i ka hoʻopili a, inā loaʻa he nīnau, nīnau aku i kā lākou kauka. Aia nā ʻōlelo no ka hoʻohana ʻana i ka lāʻau lapaʻau kahi papa inoa o nā hōʻike i ʻōlelo ʻia i hiki ke hoʻoponopono ʻia e ke kauka.
ʻO Vildagliptin 50 mg, ʻo ia ka mea nui, ka hui pū me ka thiazolidinedione, ʻo Metformin a i ʻole he lāʻau lapaʻau ʻona, ua lawe ʻia ma kahi o kēlā me kēia lā he 50 a 100 mg paha. ʻO ka maʻi diabetes, ka mea e holomua ana ka maʻi ma kahi ʻano ʻoi kino hou loa me ka hoʻomehana i ka insulin, e lawe i ka 100 mg i kēlā me kēia lā.
ʻO ka hui pūʻana i nā lāʻau lapaʻau (vildagliptin a me nā derogative sulfonylurea) e hōʻike i kahi wai no kēlā me kēia lā o 50 mg i ke kakahiaka.
Hoʻokahi hui pū hoʻokahi o nā lāʻau lapaʻau, ʻo ia hoʻi, ʻo Vildagliptin, Metformin a me nā deralona sulfonylurea, e hōʻike ana i kahi laila i kēlā me kēia lā o 100 mg.
Hoʻohana ʻia ka nui o kēlā me kēia lā i ka 50 mg i ka manawa ma ke kakahiaka, a ʻo 100 mg i loko o nā papa he ʻelua i ke kakahiaka a me ke ahiahi. Ka hoʻoponopono ʻana o ka pilikia ma ka poʻe i hana ʻia i ka hōʻeha ʻana a me ka hōʻeha ʻana o ka renal (ʻo ke ʻano, me ka pilikia ʻole).
Mālama ʻia ka lāʻau lapaʻau i kahi wahi i loaʻa ʻole ʻia no nā keiki ʻōpio, ma ke ʻano wela o 30C. ʻO 3 mau makahiki mālama i ka wā i pau ai ka manawa i hōʻike ʻia, ʻaʻole hiki ke hoʻohana i ka lāʻau lapaʻau.
ʻO nā maʻi a me nā hōʻeha
ʻAʻole nui nā contraindications i ka Vildagliptin. Hoʻohui ʻia lākou me ka intolerance pilikino o ka mea maʻi i ka mea ikaika a me nā mea ʻē aʻe, a me ke kūpaʻa genetic i ka galactose, ka nele o ka lactase a me ka malabsorption glucose-galactose.
Pono e hoʻomanaʻo ʻia ma muli o ka nele o ka noiʻi, ʻo ka palekana o ka hoʻohana ʻana i ka lāʻau lapaʻau i nā keiki a me nā ʻōpio (ma lalo o 18 mau makahiki o ka makahiki) ʻaʻole i aʻo nui ʻia.
ʻAʻohe ʻikepili ʻike noiʻi e pili ana i ka hoʻohana ʻana o vildagliptin i ka wā hāpai a me ka hoʻoulu ʻana i ka wai, no laila ua pāpā ʻia ka hoʻohana ʻia ʻana o ka lāʻau lapaʻau i kēia manawa.
Aia ma muli o ke hoʻohana ʻia ʻo Vildagliptin e like me ka monotherapy a me nā ʻano mea ʻē aʻe, hiki mai paha nā hopena like ʻole.
- monotherapy (Vildagliptin) - kahi kūlana o ka hypoglycemia, nā māhā a me ke kaumaha, constipation, peripheral edema;
- Vildagliptin, Metformin - kahi kūlana o ka hypoglycemia, pā nui, hōʻalo a me nā ʻeha;
- Vildagliptin, derivatives sulfonylurea - kahi kūlana o ka hypoglycemia, pā nui, weliweli a me nā ʻeha, asthenia (psychopathological disorder);
- ʻO Vildagliptin, kahi hua o thiazolidinedione - kahi kūlana o ka hypoglycemia, kahi liʻiliʻi he nui, paona peripheral;
- Vildagliptin, insulin (hui pū a i ʻole me ka metformin) - kahi kūlana o ka hypoglycemia, ʻeha, ka gastroesophageal reflux (e hoʻolei nei i nā kiko o ka ʻōpū i ka esophagus), nā mea haʻalulu, nausea, hoʻopihapiha ka hopena o ka hau, a me ka hoʻomehana.
I ka wā o kahi hoʻokolokolo ma hope o ke kālepa ʻana, ua nui nā maʻi maʻi e hele ana iā Vildagliptin i kahi ʻano maikaʻi ʻole e like me ka hepatitis, urticaria, exfoliation o ka ʻili, ka hoʻokumu ʻana o nā blisters a me ke kūkulu ʻana o ka pancreatitis.
Eia nō naʻe, ʻoiai kēia lāʻau lapaʻau he papa inoa nui o nā hopena o ka ʻaoʻao, ʻo ka liʻiliʻi o kā lākou hanana e liʻiliʻi. I ka hapanui o nā kūlana, he mau manawa kakaʻikahi kēia a me ko lākou hōʻike ʻana, ʻaʻole pono nā kāpae ʻia ka mālama ʻana.
Hoomaopopo loa a me nā ʻōlelo loiloi no ka hoʻohana
Ma keʻano holoʻokoʻa, mālama maikaʻi ʻia ʻo Vildagliptin e nā maʻi i nā lā a i kēlā me kēia lā o 200 mg, akā ʻaʻohe mea hou aku. Ke hoʻohana nei i kahi palaʻai nui ma mua o ka koi, aia ke kiʻekiʻe kiʻekiʻe o nā hōʻailona o ka overdose o ka lāʻau.
Pono e hoʻomanaʻo i ka wā e hoʻōki ai i ka lawe ʻana i ka lāʻau lapaʻau, hala nā ʻōuli āpau.
Nā ʻano hōʻailona o kahi overdose e kū pololei i kāna pae, no ka hoʻohālike:
- Ke hoʻohana ʻia ʻo 400 mg, ka ʻeha o ka naʻau, ke aʻa, ke kāhili a me ka hoʻonaninani o nā ʻoi loa (nā māpuna a me nā transients), e hele mai ka hoʻonui i ka maʻi lipase. Eia kekahi, hiki ke piʻi i ka mahana me ka maʻi diabetes.
- Ke hoʻohana nei i ka 600 mg, huapau ka nui o nā lima a me nā wāwae, a me ko lākou maloʻi ʻana a me ka tingling, nā mahuahua o nā waihona o ALT, CPK, myoglobin, a me C-reactive protein.
I ka hoʻomaka ʻana o nā papa hana, pono ʻoe e hoʻomaʻamaʻa i kahi noiʻi o nā hiʻohiʻona biochemical o ka ate. Inā hōʻike ka hopena i ka hana transaminase hoʻonui, pono e hoʻihoʻi hou ʻia ka huli ʻana a holo holo pinepine a paʻa mau nā hōʻailona. Inā hōʻike nā hopena o ke hoʻokolohua ALT a i ʻole kahi AST, ʻo 3 mau manawa kiʻekiʻe loa ma mua o VGN, e hoʻopau ʻia ka lāʻau lapaʻau.
Inā he mea kipi ka mea maʻi i ka pulu (no ka laʻana, jaundice), hoʻohana koke ka hoʻohana i ka lāʻau. ʻOiai ʻaʻole palupalu ka ate, ʻaʻole pāpā.
Ke koi ʻia ka lāʻau insulin, e hoʻohana wale ʻia ka vildagliptin me ka hormone. Eia kekahi, ʻaʻole hiki ke hoʻohana ʻia i kona hoʻohana ʻana i ka mālama ʻana i nā ʻano like ole o ka insulin i ka maʻi maʻi (type 1) a i ʻole ka hōʻemi kino o ka metabolism - maʻi ketoacidosis maʻi.
ʻO ka hiki ke ʻike ʻia ka vildagliptin i ka ʻike makaʻī ʻana. Eia nō naʻe, inā hele mai ka dizziness, nā mea maʻi e hoʻokau i nā kaʻa a hana paha i nā hana me nā hana hoʻokūkū pono e haʻalele i nā hana pōʻino e like me ka lōʻihi o ka hopena.
ʻO ke kumukūʻai, nā loiloi a me nā hoʻohālike
Mai ka mea i kau ʻia ka lāʻau lapaʻau Vildagliptin (mea hana ʻo Switzerland), ma muli o kāna kumukūʻai ʻaʻole e haʻahaʻa loa. Eia nō naʻe, hiki i kekahi mea maʻi me kahi uku haʻahaʻa ke hiki i ka lāʻau lapaʻau. Hiki ke kūʻai aku i ka mea hana ma ka hale kūʻai aiʻole kauoha i ka pūnaewele.
ʻO ke kumukūʻai o ka lāʻau lapaʻau (28 mau papa o nā papa he 50 mg) hoʻololi mai ka 750 a 880 mau rubles Lūkini.
ʻO nā manaʻo no nā kauka a me nā mea maʻi e pili ana i ka hoʻohana ʻana i nā lāʻau lapaʻau, he maikaʻi loa nā loiloi.
ʻO nā mea maʻi me ka maʻi mellitus o ke ʻano lua i lawe i nā peni e hōʻike i nā pono o kēia mau lāʻau.
- ka wikiwiki wikiwiki i ka hilo me ka mālama ʻana i loko o nā palena maʻamau;
- mālie o ka hoʻohanaʻana i ke ʻano dosage;
- loaʻa pinepine nā hōʻike no ka hopena maikaʻiʻole o ka lāʻau.
Wahi a kēia, hiki i ka lāʻau lapaʻau ke kiʻi i kahi lāʻau hypoglycemic maikaʻi i ka hakakā me nā maʻi maʻi type 2. Akā i kekahi manawa e pili ana i nā contraindications a i ʻole ka pōʻino paha, pono ʻoe e hōʻole i ka hoʻohana ʻana i ka lāʻau. I kēlā mau kūlana, e hāʻawi ana ka loea i ka mea lapaʻau i nā mea kikowaena - nā mea ʻālana e loaʻa ka hopena o ka therapeutic like me Vildagliptin. E pili ana kēia:
- Onglisa. ʻO ka mea hana hoʻoheheheʻe na saxagliptin. Hoʻololi ke kumukūʻai ma ka palena o 1900 rubles.
- Trazenta. ʻO ke ʻano hana he linagliptin. ʻO ka kumu kumukūʻai he 1750 rubles.
- Hoavius. ʻO ka waiwai kahi sitagliptin. ʻO ka uku kumukūʻai he 1670 rubles.
E like me kāu e ʻike ai, loaʻa nā analogues i nā ʻokoʻa like i kā lākou kāʻei. I kēia hihia, pono ke koho ke kauka i kēia lāʻau lapaʻau i hiki ʻole ke hoʻokau i nā hopena maikaʻi ʻole o ka mea maʻi. Pono e nānāʻia ua kohoʻia nā analogues ma muli o ke kumu kumu, he hana nui nō hoʻi.
ʻO ka lāʻau lapaʻau Galvus vildagliptin (Latin - Vildagliptinum), hiki ke ʻike i kahi lāʻau lapaʻau hypoglycemic maikaʻi, i lawe ʻia ʻelua me ke kumu a hui pū me nā lāʻau ʻē aʻe. No ka laʻana, ka hui pū ʻana o vildagliptin, metformin me nā olony sulfonylurea. Ua papa ʻia ke hoʻohana kūʻokoʻa ʻana o ka lāʻau lapaʻau, pono ʻoe e hoʻopili mau i nā ʻōlelo a ke kauka. Eia, ma ka hihia inā ʻaʻole hiki ke lawe ʻia ka lāʻau lapaʻau no kekahi kumu, ua kuhikuhi ke kauka i nā mea hoʻohālikelike. Ke hoʻomau nei ke wikiō ma kēia ʻatikala i ke kumumanaʻo o ka lāʻau lapaʻau no ka maʻi diabetes.
